Keyphrases
Glioblastoma
100%
Temozolomide
41%
Glioblastoma multiforme
32%
Tumor
30%
Blood-brain Barrier
24%
Xenograft
18%
Glioblastoma Cells
18%
Patient-derived Xenograft
16%
Brain Tumor
15%
Glioma
15%
Glioblastoma Xenografts
12%
Radiation Therapy
11%
Methylguanine Methyltransferase
10%
Patient-derived
10%
Epidermal Growth Factor Receptor
10%
Central Nervous System
10%
Radiosensitization
9%
Phosphorylation
8%
Drug Delivery
8%
EGFRvIII
8%
Tumor Cells
8%
Xenograft Model
7%
Temozolomide Resistance
7%
Combination Therapy
7%
Ataxia Telangiectasia mutated
7%
Radiotherapy
7%
Mammalian Target of Rapamycin (mTOR)
6%
Platelet-derived Growth Factor Receptor (PDGFR)
6%
Phase II Trial
6%
P-glycoprotein (P-gp)
6%
Brain Distribution
6%
Primary Brain Tumor
5%
Erlotinib
5%
Clinical Trials
5%
Mouse Model
5%
DNA Damage
5%
System Distributions
5%
Glioma Cells
5%
Newly Diagnosed Glioblastoma
5%
Melanoma Brain Metastases
5%
Glioma Stem Cells
5%
Cancer Treatment
5%
Antitumor Activity
5%
Phosphoinositide 3-kinase (PI3K)
5%
PARP Inhibitor (PARPi)
5%
Treatment Group
5%
Drug Transporters
5%
Measles Virus
5%
Brain Metastases
5%
Isocitrate Dehydrogenase 1 (IDH1)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
91%
Neoplasm
43%
Temozolomide
38%
Blood-Brain Barrier
25%
Intracranial Tumor
20%
Malignant Neoplasm
14%
Epidermal Growth Factor Receptor
14%
Brain Metastasis
11%
Effusion
11%
Ataxia Telangiectasia
9%
DNA Methyltransferase
8%
Radiosensitizing Agent
7%
Combination Therapy
7%
Chemotherapy
6%
Pharmacokinetics
6%
Treatment Group
6%
P-Glycoprotein
6%
Clinical Trial
6%
Melanoma
5%
Phosphotransferase Inhibitor
5%
Protein P53
5%
Erlotinib
5%
Mouse Model
5%
Phosphotransferase
5%
Diseases
5%
ABCG2
5%
Medicine and Dentistry
Glioblastoma
83%
Neoplasm
35%
Xenograft
35%
Temozolomide
25%
Radiation Therapy
18%
Ganglioglioma
18%
Epidermal Growth Factor Receptor
14%
Intracranial Tumor
12%
In Vitro
11%
Cancer
9%
Blood Brain Barrier
8%
Brain Metastasis
7%
Clinical Trial
6%
Tumor Cell
6%
Biological Marker
6%
Malignant Neoplasm
5%
Melanoma
5%
Magnetic Resonance Imaging
5%
DNA Methyltransferase
5%
Combination Therapy
5%